CD4⁺ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours

REFERENCES

• Willis RA. The spread of tumours in the human body. London: Butterworths; 1973. p. 175–83.
   Google Scholar
• Daly JM, Kemeny NE. Metastatic cancer to the liver: In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p.2551–70.
   Google Scholar
• Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterization and clinical utilization. Int J Cancer 1991; 49: 19–24.
   Google Scholar
• Alexander HR, Barlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16: 1479–89.
   PubMed Web of Science ®Google Scholar
• Linehan DC, Goedegebuure PS, Eberlein TJ. Vaccine therapy for cancer. Ann Surg Oncol 1996; 3:219–28.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Chang KJ, Lee CS, Chen KM. Selective depression of T-lymphocyte subsets in gastric cancer patients: an implication of immunotherapy. J Surg Oncol 1994; 55: 164–9.
   Google Scholar
• Tancini G, Bami S, Rescaldani R, Fiorelli G, Viviani S, Lissoni P. Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. Oncology 1990; 47: 381–4.
   PubMedGoogle Scholar
• Richner J, Ambinder EP, Hoffmann K, Feuer EJ, Bekesi G. Number of helper T cells and phytohem-agglutinin stimulation correlate in cancer patients. Cancer Immunol Immun 1991; 34: 138–42.
   Google Scholar
• Saleh MN, Goldman SJ, LoBuglio AF, Beall AC, Sabio H, McCord MC, Minasian L, Alpaugh K, Weiner LM, Munn DH. CD16 + monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 1995; 85: 2910–17.
   PubMed Web of Science ®Google Scholar
• O'Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS, Kerin MJ, Lee PWR, Monson JRT. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 1998; 4: 1943–8.
   PubMed Web of Science ®Google Scholar
• Garrioch DB, Good RA, Gatti RA. Lymphocyte response to P.H.A. in patients with non-lymphoid tumours. Lancet 1970; 1: 618.
   Google Scholar
• Melichar B, Jandik P, Krejsek J, Solichova D, Drahosova M, Skopec F, Mergancova J, Voboril Z. Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. Tumori 1996; 82: 218–20.
   PubMed Web of Science ®Google Scholar
• Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner ER, Werner-Felmayer G, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prey 1991; 15: 483–90.
   Google Scholar
• Melichar B, Jandik P, Solichova D, Bures J, Lukes J, Mergancova J, Voboril Z. Urinary neopterin excretion in colorectal cancer. Onkologie 1994; 17: 434–6.
   Google Scholar
• Robinson E, Segal R, Struminger L, Faraggi D, El ad-Yarum R, Mekori T. Lymphocyte subpopul-ations in patients with multiple primary tumors. Cancer 1999; 85: 2073–6.
   Google Scholar
• Patanaphan V, Salazar OM. Colorectal cancer: metastatic patterns and prognosis. Southern Med J 1993; 86: 38–41.
   PubMed Web of Science ®Google Scholar
• Venook AP, Warren RS. Regional chemotherapy approaches for primary and metastatic liver tumors. Surg Oncol Clin N Amer 1996; 5: 411–27.
   PubMedGoogle Scholar
• Keilholz U, Schlag P, Tilgen W, Brado B, Galm F, Gorich J, Kauffmann GW, Moller P, Schneider S, Hunstein W. Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer 1992; 69: 2172–5.
   PubMed Web of Science ®Google Scholar
• Matsuhashi N, Moriyama T, Nakamura I, Ishikawa T, Ohnishi S, Nakagama H, Imawari M, Takaku F. Adoptive immunotherapy of primary and metastatic liver cancer via hepatic artery catheter. Eur J Cancer 1990; 26: 1106–7.
   PubMedGoogle Scholar
• Adleman LM, Wofsy D. T-cell homeostasis: implications in HIV infection. J Acquired Immunodeficiency Syndromes 1993; 6: 144–52.
   PubMed Web of Science ®Google Scholar
• Margolick JB, Munoz A, Donnenberg AD, Park LP, Galai N, Giorgi JV, O'Gorman RG, Ferbas J. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nat Med 1995; 1: 674–80.
   Google Scholar
• Fuchs D, Banekovich M, Hausen A, Hutterer J, Reibnegger G, Werner ER, Gschnait FD, Dierich MP, Wachter H. Neopterin estimation compared with the ratio of T-cell subpopulations in persons infected with human immunodeficiency virus-1. Clin Chem 1988; 34: 2415–7.
   Google Scholar
• Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81–141.
   Google Scholar
• Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A. Apoptosis occurs pre-dominantly in bystander cells and not in pro-ductively infected cells of HIV- and SW-infected lymph nodes. Nat Med 1995; 1: 129–34.
   PubMed Web of Science ®Google Scholar
• Muro-Cacho CA, Pantaleo G, Fauci AS. Analysis of apoptosis in lymph nodes of HP/-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995; 154: 5555–66.
   Google Scholar
• Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander NH, Novick AC, Finke JH. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999; 5: 1219–29.
   Google Scholar
• Yacyshyn MBB, Poppema S, Berg A, MacLean GD, Reddish MA, Meikle A, Longenecker BM. CD69 + and HLA-DR + acti-vation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 1995; 61: 470–74.
   Google Scholar
• Jaffe JS, Strober W, Sneller MC. Functional abnor-malities of CD8 + T cells define a unique subset of patients with common variable immuno-deficiency. Blood 1993; 82: 192–201.
   Google Scholar
• Wright JJ, Wagner DK, Blaese RM, Hagengruber C, Waldman TA, Fleisher TA. Characterization of common variable immuno-deficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features. Blood 1990; 76: 2046–51.
   PubMed Web of Science ®Google Scholar
• Reddy MM, Weissman AM, Mazza DS, Meriney DK, Johns M, Carrabis S, Grieco MH. Circulating elevated levels of soluble CD23, interleukin-4, and CD20 + CD23 + lymphocytes in atopic subjects with elevated serum IgE concen-trations. Ann Allergy 1992; 69: 131–4.
   Google Scholar
• Monteneiro J, Batliwalla F, Ostrer H, Gregersen PK. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28 + CD8 + counterparts. J Immunol 1996; 156: 3587–90.
   PubMedGoogle Scholar
• Ziegler-Heitbrock HWL. Heterogeneity of human blood monocytes: The CD14 + CD16 + subpopul-ation. Immunol Today 1996; 17: 424–8.
   PubMedGoogle Scholar
• Fidler U. Therapy of cancer metastasis by systemic activation of macrophages. Adv Pharmacol 1994; 30: 271–326.
   PubMedGoogle Scholar
• Laurence J. T-cell subsets in health, infectious disease, and idiopathic CD4 + T lymphocytopenia. Ann Intern Med 1993; 119: 55–62.
   PubMed Web of Science ®Google Scholar
• Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, Deneux L, Gorin I, Negrier S, Mathiot C, Pouillart P, Fridman WH. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multi-institutional study. J Clin Oncol 1996; 14: 1697–703.
   PubMed Web of Science ®Google Scholar